Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.